Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017

Pharmaceutical Investing

Spring Bank Pharmaceuticals (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its fourth quarter and full-year 2017 financial results and provided an update on recent developments. As quoted in the press release: Net loss: The company’s net loss for the year ended December …

Spring Bank Pharmaceuticals (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its fourth quarter and full-year 2017 financial results and provided an update on recent developments.

As quoted in the press release:

Net loss: The company’s net loss for the year ended December 31, 2017 was $(27.7) million, or $(2.48) per share, compared to $(17.4) million for the year ended December 31, 2016, or $(2.39) per share. Net loss for the quarter ended December 31, 2017 was $(1.5) million, or $(0.11) per share, compared to net loss for the quarter ended December 31, 2016 of $(2.4) million, or $(0.28) per share.

Click here to read the full press release.

The Conversation (0)
×